Undiagnosed RASopathies in infertile men

Anna-Grete Juchnewitsch, Kristjan Pomm, Avirup Dutta, Erik Tamp, Anu Valkna, Kristiina Lillepea, Eisa Mahyari, Stanislav Tjagur, Galina Belova, Viljo Kübarsepp, Helen Castillo‐Madeen, Antoni Riera‐Escamilla, Lisanna Põlluaas, Liina Nagirnaja, Olev Poolamets, Vladimir Vihljajev, Mailis Sütt, Nassim Versbraegen, Sofia Papadimitriou, Robert I. McLachlan, Keith Jarvi, Peter N. Schlegel, Sven Tennisberg, Paul Korrovits, Katinka A. Vigh‐Conrad, Moira K. O’Bryan, Kenneth I. Aston, Tom Lenaerts, Donald F. Conrad, Laura Kasak, Margus Punab, Maris LaanFrontiers in Endocrinology 2024 · DOI

TL;DR

This study reveals that undiagnosed RASopathies—a group of genetic syndromes affecting the MAPK signaling pathway—are a significant hidden cause of male infertility. Researchers found that men with both spermatogenic failure and a history of undescended testicles (cryptorchidism) are over 13 times more likely to carry pathogenic variants in RASopathy-linked genes, often accompanied by systemic health issues like heart defects and rare malignancies.

What Problem Does This Paper Address?

RASopathies (such as Noonan syndrome) are relatively common genetic conditions (1 in 1,000 people) caused by mutations in the Ras/MAPK pathway. While they are typically diagnosed in childhood due to distinct facial features, heart defects, and developmental delays, many cases remain mild or undiagnosed.

A key feature of RASopathies in males is cryptorchidism (CR)—undescended testicles—which occurs in over 50% of affected men and is a major risk factor for spermatogenic failure (SPGF) later in life. The authors hypothesized that a subset of men seeking help for infertility are actually "stealth" RASopathy patients whose primary clinical complaint is poor sperm quality, but who may have other underlying systemic health risks.

Methods

The researchers employed a multi-stage genomic and clinical approach:

  • Exome Sequencing: They performed whole-exome sequencing (WES) on the ESTAND cohort (521 infertile men and 323 fertile controls).
  • Targeted Screening: They specifically looked for likely pathogenic or pathogenic (LP/P) variants in 22 genes known to cause RASopathies.
  • Validation: Findings were validated using the GEMINI cohort, a massive international dataset of 1,733 men.
  • Phenotyping: Beyond genetics, they analyzed testicular biopsies (histopathology), protein expression (immunohistochemistry), and utilized single-cell RNA sequencing data to see where these genes are active in the human testis.
  • Clinical Follow-up: Patients identified with mutations underwent a multidisciplinary clinical assessment to check for other RASopathy symptoms.

Datasets

  • ESTAND (Estonian ANDrology) cohort: 844 men recruited in Estonia, providing the primary discovery set.
  • GEMINI (Genetics of Male Infertility Initiative): 1,416 SPGF cases and 317 fertile men used for independent validation.
  • HISTA (Human Infertility Single-cell Testis Atlas): Used to map the expression of RASopathy genes across different testicular cell types (spermatogonia, Sertoli cells, etc.).

Key Insights and Ideas

  • The "Sentinel" Symptom: Infertility may serve as the primary indicator for a systemic genetic syndrome that was missed during childhood.
  • Syndromic Enrichment: The link is strongest in men with a "double hit": a history of cryptorchidism and current spermatogenic failure. In this subgroup, the prevalence of RASopathy mutations was 3.9%, compared to just 0.3% in the control group.
  • Direct Testicular Role: By looking at single-cell data, the authors found that RASopathy genes are highly expressed in both the "support" cells (Sertoli/Leydig) and the sperm-producing cells themselves. This suggests the infertility isn't just a side effect of the testicles being undescended; the mutation likely disrupts sperm development directly.
  • Hidden Comorbidities: Upon re-examining the mutation carriers, the researchers found a high rate of previously ignored symptoms: skeletal anomalies, heart valve defects, and skin conditions (like cafe-au-lait spots).

Key Results

  • Genetic Hits: Identified LP/P variants in genes including PTPN11, SOS1, SOS2, LZTR1, SPRED1, NF1, MAP2K1, and MRAS.
  • Statistical Significance: The "CR and SPGF" subgroup showed a 13-fold enrichment of RASopathy findings compared to controls ($p = 5.5 \times 10^{-3}$).
  • Total Discovery: Across both cohorts, 17 men were identified with undiagnosed RASopathies.
  • Cancer Risk: Alarmingly, four of the identified carriers had histories of rare malignancies, including schwannomatosis, pancreatic cancer, and testicular cancer, highlighting the importance of diagnosis for long-term health monitoring.

Limitations and Future Work

  • Sample Size: While the enrichment is statistically significant, the absolute number of carriers found is small, which is typical for rare genetic syndromes.
  • De Novo Confirmation: The study lacked parental DNA for most subjects, making it difficult to determine if these mutations were inherited or occurred spontaneously (de novo).
  • Clinical Integration: The authors advocate for a shift in clinical practice: andrologists should consider genetic screening for RASopathies in infertile men with a history of cryptorchidism.
  • Future Directions: Further research is needed to determine if these patients respond differently to assisted reproductive technologies (ART) and to establish standardized screening protocols for associated cancer risks in this specific adult population.

Summary updated

Abstract

RASopathies are syndromes caused by congenital defects in the Ras/mitogen-activated protein kinase (MAPK) pathway genes, with a population prevalence of 1 in 1,000. Patients are typically identified in childhood based on diverse characteristic features, including cryptorchidism (CR) in >50% of affected men. As CR predisposes to spermatogenic failure (SPGF; total sperm count per ejaculate 0-39 million), we hypothesized that men seeking infertility management include cases with undiagnosed RASopathies. Likely pathogenic or pathogenic (LP/P) variants in 22 RASopathy-linked genes were screened in 521 idiopathic SPGF patients (including 155 CR cases) and 323 normozoospermic controls using exome sequencing. All 844 men were recruited to the ESTonian ANDrology (ESTAND) cohort and underwent identical andrological phenotyping. RASopathy-specific variant interpretation guidelines were used for pathogenicity assessment. LP/P variants were identified in <i>PTPN11</i> (two), <i>SOS1</i> (three), <i>SOS2</i> (one), <i>LZTR1</i> (one), <i>SPRED1</i> (one), <i>NF1</i> (one), and <i>MAP2K1</i> (one). The findings affected six of 155 cases with CR and SPGF, three of 366 men with SPGF only, and one (of 323) normozoospermic subfertile man. The subgroup "CR and SPGF" had over 13-fold enrichment of findings compared to controls (3.9% <i>vs.</i> 0.3%; Fisher's exact test, <i>p</i> = 5.5 × 10<sup>-3</sup>). All ESTAND subjects with LP/P variants in the Ras/MAPK pathway genes presented congenital genitourinary anomalies, skeletal and joint conditions, and other RASopathy-linked health concerns. Rare forms of malignancies (schwannomatosis and pancreatic and testicular cancer) were reported on four occasions. The Genetics of Male Infertility Initiative (GEMINI) cohort (1,416 SPGF cases and 317 fertile men) was used to validate the outcome. LP/P variants in <i>PTPN11</i> (three), <i>LZTR1</i> (three), and <i>MRAS</i> (one) were identified in six SPGF cases (including 4/31 GEMINI cases with CR) and one normozoospermic man. Undiagnosed RASopathies were detected in total for 17 ESTAND and GEMINI subjects, 15 SPGF patients (10 with CR), and two fertile men. Affected RASopathy genes showed high expression in spermatogenic and testicular somatic cells. In conclusion, congenital defects in the Ras/MAPK pathway genes represent a new congenital etiology of syndromic male infertility. Undiagnosed RASopathies were especially enriched among patients with a history of cryptorchidism. Given the relationship between RASopathies and other conditions, infertile men found to have this molecular diagnosis should be evaluated for known RASopathy-linked health concerns, including specific rare malignancies.
BibTeX
@inproceedings{juchnewitsch2024undiagnosed,
  author = {Anna-Grete Juchnewitsch and Kristjan Pomm and Avirup Dutta and Erik Tamp and Anu Valkna and Kristiina Lillepea and Eisa Mahyari and Stanislav Tjagur and Galina Belova and Viljo Kübarsepp and Helen Castillo‐Madeen and Antoni Riera‐Escamilla and Lisanna Põlluaas and Liina Nagirnaja and Olev Poolamets and Vladimir Vihljajev and Mailis Sütt and Nassim Versbraegen and Sofia Papadimitriou and Robert I. McLachlan and Keith Jarvi and Peter N. Schlegel and Sven Tennisberg and Paul Korrovits and Katinka A. Vigh‐Conrad and Moira K. O’Bryan and Kenneth I. Aston and Tom Lenaerts and Donald F. Conrad and Laura Kasak and Margus Punab and Maris Laan},
  title = {{Undiagnosed RASopathies in infertile men}},
  booktitle = {Frontiers in Endocrinology},
  year = {2024},
  doi = {10.3389/fendo.2024.1312357},
}
Figure